Published in Cancer Res on August 15, 2008
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature (2010) 3.24
Androgen receptor signaling in prostate cancer development and progression. J Carcinog (2011) 1.90
Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy. Prostate (2014) 1.47
Minireview: Alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol (2011) 1.43
Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. Br J Cancer (2012) 1.41
Activation of beta-Catenin in mouse prostate causes HGPIN and continuous prostate growth after castration. Prostate (2009) 1.30
Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res (2010) 1.29
Cancer biomarker discovery: the entropic hallmark. PLoS One (2010) 1.26
Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells. Prostate (2010) 1.18
Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells. Mol Cancer Res (2010) 1.12
Flavokawain B, a kava chalcone, induces apoptosis via up-regulation of death-receptor 5 and Bim expression in androgen receptor negative, hormonal refractory prostate cancer cell lines and reduces tumor growth. Int J Cancer (2010) 1.12
Dietary energy balance modulates prostate cancer progression in Hi-Myc mice. Cancer Prev Res (Phila) (2011) 1.10
PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer. Cancer Res (2012) 1.10
NF-κB gene signature predicts prostate cancer progression. Cancer Res (2014) 1.09
The expression of androgen-responsive genes is up-regulated in the epithelia of benign prostatic hyperplasia. Prostate (2009) 1.08
Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells. Prostate (2009) 1.08
Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic. Cancer Metastasis Rev (2013) 1.08
KAI1 gene is engaged in NDRG1 gene-mediated metastasis suppression through the ATF3-NFkappaB complex in human prostate cancer. J Biol Chem (2011) 1.07
Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol Cell Biol (2012) 1.02
Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives. World J Urol (2011) 0.99
Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone. PLoS One (2013) 0.99
LRP16 integrates into NF-κB transcriptional complex and is required for its functional activation. PLoS One (2011) 0.99
beta-TrCP inhibition reduces prostate cancer cell growth via upregulation of the aryl hydrocarbon receptor. PLoS One (2010) 0.99
New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer. Nutr Cancer (2011) 0.98
Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort. Cancer Prev Res (Phila) (2012) 0.98
Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression. Oncogene (2014) 0.97
NF-κB signaling in prostate cancer: a promising therapeutic target? World J Urol (2011) 0.95
Minireview: modulation of hormone receptor signaling by dietary anticancer indoles. Mol Endocrinol (2009) 0.94
Celastrol suppresses tumor cell growth through targeting an AR-ERG-NF-κB pathway in TMPRSS2/ERG fusion gene expressing prostate cancer. PLoS One (2013) 0.93
Mouse models of prostate cancer: picking the best model for the question. Cancer Metastasis Rev (2014) 0.93
Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting. Am J Clin Exp Urol (2014) 0.91
Evaluation of nuclear factor κB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. BJU Int (2010) 0.91
Phenethyl isothiocyanate sensitizes androgen-independent human prostate cancer cells to docetaxel-induced apoptosis in vitro and in vivo. Pharm Res (2010) 0.90
Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression. Cancer Res (2009) 0.90
Persistent inflammation leads to proliferative neoplasia and loss of smooth muscle cells in a prostate tumor model. Neoplasia (2011) 0.89
Activation of nuclear factor κB (NF-κB) in prostate cancer is mediated by protein kinase C epsilon (PKCepsilon). J Biol Chem (2012) 0.88
Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKα. J Immunol (2013) 0.88
The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis. Front Oncol (2014) 0.87
Androgen receptor regulates expression of the MUC1-C oncoprotein in human prostate cancer cells. Prostate (2011) 0.87
Function of phosphorylation of NF-kB p65 ser536 in prostate cancer oncogenesis. Oncotarget (2015) 0.86
A screen for transcription factor targets of glycogen synthase kinase-3 highlights an inverse correlation of NFκB and androgen receptor signaling in prostate cancer. Oncotarget (2014) 0.86
Diet components can suppress inflammation and reduce cancer risk. Nutr Res Pract (2014) 0.85
AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis. Cancer Res (2014) 0.85
Constitutive activity of the androgen receptor. Adv Pharmacol (2014) 0.84
Diabetes protects from prostate cancer by downregulating androgen receptor: new insights from LNCaP cells and PAC120 mouse model. PLoS One (2013) 0.84
The nrf1 and nrf2 balance in oxidative stress regulation and androgen signaling in prostate cancer cells. Cancers (Basel) (2010) 0.83
Targeting neuroendocrine prostate cancer: molecular and clinical perspectives. Front Oncol (2015) 0.83
IκB kinases modulate the activity of the androgen receptor in prostate carcinoma cell lines. Neoplasia (2012) 0.83
Factors implicated in radiation therapy failure and radiosensitization of prostate cancer. Prostate Cancer (2011) 0.82
NF-kappaB activation enhances cell death by antimitotic drugs in human prostate cancer cells. Mol Cancer (2010) 0.81
Mash1 expression is induced in neuroendocrine prostate cancer upon the loss of Foxa2. Prostate (2012) 0.80
Androgen receptor footprint on the way to prostate cancer progression. World J Urol (2011) 0.80
A novel pathway links oxidative stress to loss of insulin growth factor-2 (IGF2) imprinting through NF-κB activation. PLoS One (2014) 0.78
Combination of Lipitor and Celebrex inhibits prostate cancer VCaP cells in vitro and in vivo. Anticancer Res (2014) 0.77
The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis. Carcinogenesis (2015) 0.77
Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle. Open Access J Urol (2010) 0.77
Neuropeptide-inducible upregulation of proteasome activity precedes nuclear factor kappa B activation in androgen-independent prostate cancer cells. Cancer Cell Int (2012) 0.76
TNF signaling mediates an enzalutamide-induced metastatic phenotype of prostate cancer and microenvironment cell co-cultures. Oncotarget (2015) 0.76
Cytokine effects on cell viability and death of prostate carcinoma cells. Biomed Res Int (2014) 0.75
Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression. Oncotarget (2016) 0.75
Targeting IκB Kinase β/NF-κB Signaling in Human Prostate Cancer by a Novel IκB Kinase β Inhibitor CmpdA. Mol Cancer Ther (2016) 0.75
Neuroendocrine prostate cancer (NEPCa) increased the neighboring PCa chemoresistance via altering the PTHrP/p38/Hsp27/androgen receptor (AR)/p21 signals. Oncogene (2016) 0.75
Total glucosides of paeony inhibits lipopolysaccharide-induced proliferation, migration and invasion in androgen insensitive prostate cancer cells. PLoS One (2017) 0.75
Synthesis and in vitro characterization of ionone-based compounds as dual inhibitors of the androgen receptor and NF-κB. Invest New Drugs (2013) 0.75
The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol (1996) 22.30
NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol (1998) 21.48
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Nuclear factor-kappaB in cancer development and progression. Nature (2006) 18.31
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev (1995) 9.31
Androgen receptor in prostate cancer. Endocr Rev (2004) 7.92
Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell (2003) 6.38
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res (2001) 5.11
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res (2005) 5.04
Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res (2001) 4.12
IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest (2005) 4.07
A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res (2001) 3.37
Duration and intensity of NF-kappaB activity determine the severity of endotoxin-induced acute lung injury. J Immunol (2006) 2.96
A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology (2000) 2.69
Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol (2008) 2.51
Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development (2005) 2.31
The androgen receptor gene mutations database (ARDB): 2004 update. Hum Mutat (2004) 2.25
Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res (2005) 1.88
Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem (2006) 1.85
NF-kappaB activation in development and progression of cancer. Cancer Sci (2007) 1.67
Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol (2004) 1.64
Targeted immunomodulation of the NF-kappaB pathway in airway epithelium impacts host defense against Pseudomonas aeruginosa. J Immunol (2006) 1.62
Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res (2006) 1.61
A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res (2001) 1.59
NF-kappaB in solid tumors. Biochem Pharmacol (2006) 1.57
NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol (2002) 1.55
Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer (2005) 1.49
Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. Cancer Res (2007) 1.41
Selective I kappa B kinase expression in airway epithelium generates neutrophilic lung inflammation. J Immunol (2003) 1.34
Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Res (1998) 1.33
Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. Clin Cancer Res (2006) 1.30
Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer (1999) 1.27
Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer (2005) 1.26
NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res (2004) 1.24
Expression of NF-kappaB in prostate cancer lymph node metastases. Prostate (2004) 1.18
Characterization of antibodies to androgen-dependent secretory proteins of the mouse dorsolateral prostate. Endocrinology (1990) 1.14
Neuroendocrine cells in prostate cancer. Crit Rev Eukaryot Gene Expr (2004) 1.12
Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells. Cancer Res (2007) 1.03
Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Ann Oncol (2001) 0.96
Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume. Urology (2000) 0.94
Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP. Prostate (2006) 0.93
Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Prostate (1997) 0.92
Lymphocytes lacking I kappa B-alpha develop normally, but have selective defects in proliferation and function. J Immunol (2000) 0.92
Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate. Urol Res (1995) 0.87
Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer. J Formos Med Assoc (2003) 0.86
Decreased retinoid X receptor-alpha protein expression in basal cells occurs in the early stage of human prostate cancer development. Cancer Epidemiol Biomarkers Prev (2004) 0.86
RAG2-/-, I kappa B-alpha-/- chimeras display a psoriasiform skin disease. J Invest Dermatol (2000) 0.84
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med (2006) 13.54
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 13.03
Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 11.83
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med (2004) 11.29
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol (2005) 10.48
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
Dynamics of chronic myeloid leukaemia. Nature (2005) 6.63
Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell (2003) 6.38
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med (2008) 5.54
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med (2007) 5.06
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A (2005) 4.70
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med (2005) 4.44
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest (2007) 4.07
The protein kinase IKKepsilon regulates energy balance in obese mice. Cell (2009) 3.93
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell (2004) 3.79
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell (2008) 3.68
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood (2002) 3.60
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell (2013) 3.59
Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol (2008) 3.56
Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med (2005) 3.52
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol (2004) 3.51
Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife (2013) 3.49
Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res (2003) 3.36
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res (2006) 3.31
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature (2011) 3.18
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res (2011) 3.15
The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol Endocrinol (2003) 3.01
Duration and intensity of NF-kappaB activity determine the severity of endotoxin-induced acute lung injury. J Immunol (2006) 2.96
AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem (2003) 2.88
Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A (2005) 2.85
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell (2009) 2.73
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature (2010) 2.65
Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res (2006) 2.59
Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood (2004) 2.57
Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis. Am J Respir Crit Care Med (2009) 2.53
Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2010) 2.53
ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res (2012) 2.51
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell (2008) 2.48
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell (2007) 2.43
Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes. Nature (2005) 2.43
Bronchial secretory immunoglobulin a deficiency correlates with airway inflammation and progression of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2011) 2.42
Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. Am J Physiol Lung Cell Mol Physiol (2008) 2.39
Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene (2005) 2.35
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood (2002) 2.33
Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development (2005) 2.31
ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med (2013) 2.26
MicroRNA-181b regulates NF-κB-mediated vascular inflammation. J Clin Invest (2012) 2.24
Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov (2013) 2.15
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol (2011) 2.14
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A (2002) 2.13
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci U S A (2006) 2.13
Characterization of fibroblast-specific protein 1 in pulmonary fibrosis. Am J Respir Crit Care Med (2004) 2.10
Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res (2012) 2.09
Airway epithelium controls lung inflammation and injury through the NF-kappa B pathway. J Immunol (2007) 2.07
Concern TLR4 is necessary for hyaluronan-mediated airway hyperresponsiveness after ozone inhalation. Am J Respir Crit Care Med (2009) 2.07
Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10. Am J Respir Cell Mol Biol (2004) 2.06
Macrophages are necessary for maximal nuclear factor-kappa B activation in response to endotoxin. Am J Respir Cell Mol Biol (2002) 2.05
Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res (2007) 2.04
Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol (2002) 2.02
HS2 enhancer function is blocked by a transcriptional terminator inserted between the enhancer and the promoter. J Biol Chem (2004) 2.01
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res (2006) 1.98
Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene (2003) 1.96
Expression and role of Foxa proteins in prostate cancer. Prostate (2006) 1.96
Monocytes are potent facilitators of alveolar neutrophil emigration during lung inflammation: role of the CCL2-CCR2 axis. J Immunol (2003) 1.95
Regional neural activation defines a gateway for autoreactive T cells to cross the blood-brain barrier. Cell (2012) 1.90
Hepsin promotes prostate cancer progression and metastasis. Cancer Cell (2004) 1.89
Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis. Proc Natl Acad Sci U S A (2007) 1.89
β-catenin in the alveolar epithelium protects from lung fibrosis after intratracheal bleomycin. Am J Respir Crit Care Med (2013) 1.89
JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc Natl Acad Sci U S A (2012) 1.88
Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res (2005) 1.88
Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov (2012) 1.87
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A (2011) 1.87
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin Cancer Res (2003) 1.83
Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res (2005) 1.79
Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. Proc Natl Acad Sci U S A (2006) 1.77
Low-level laser therapy activates NF-kB via generation of reactive oxygen species in mouse embryonic fibroblasts. PLoS One (2011) 1.76